Risk Factors for Brain Metastases in Patients with Non-small-cell Lung Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2018 Nov 10

PMID 30411543

Citations 26

Authors

Ning An

Wang Jing

Haoyi Wang

Ji Li

Yang Liu

Jinming Yu

Hui Zhu

Affiliations

Soon will be listed here.

Abstract

Brain metastases (BM) are severe incidents in patients with non-small-cell lung cancer (NSCLC). The controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms of survival benefit prompted us to explore the possible risk factors for BM in NSCLC and identify the potential population most likely to benefit from PCI. Risk factors for brain metastases in NSCLC are reviewed in this article. Identifying patients with a higher risk of BM could possibly increase the benefit of PCI while reducing the discomfort and risks caused by unnecessary invasive procedures in the NSCLC patient population. Future studies might focus on finding a solid basis for the prediction of the occurrence of brain metastases and for the therapeutic decision on the use of PCI.

Citing Articles

Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma.

Dunne E, Fick C, Mastrogiacomo B, Tan K, Toumbacaris N, Vanstraelen S JTCVS Open. 2025; 22():458-469.

PMID: 39780816 PMC: 11704575. DOI: 10.1016/j.xjon.2024.09.030.

Development of brain metastases in non-small-cell lung cancer: high-risk features.

Winslow N, Boyle J, Miller W, Wang Y, Geoffroy F, Tsung A CNS Oncol. 2024; 13(1):2395804.

PMID: 39264427 PMC: 11404603. DOI: 10.1080/20450907.2024.2395804.

Predictive risk score for isolated brain metastasis in non-small cell lung cancer.

Merino K, Bassiri A, Parker B, Bruno D, Linden P, Sinopoli J J Thorac Dis. 2024; 16(6):3794-3804.

PMID: 38983167 PMC: 11228727. DOI: 10.21037/jtd-23-1668.

The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung.

Kong C, Yin X, Zou J, Ma C, Liu K BMC Cancer. 2024; 24(1):454.

PMID: 38605303 PMC: 11010275. DOI: 10.1186/s12885-024-12158-0.

AI-guided histopathology predicts brain metastasis in lung cancer patients.

Zhou H, Watson M, Bernadt C, Lin S, Lin C, Ritter J J Pathol. 2024; 263(1):89-98.

PMID: 38433721 PMC: 11210939. DOI: 10.1002/path.6263.

References

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z . The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected]. Anticancer Res. 2014; 34(9):5193-8. View

Wu Y, Zhong W, Li L, Zhang X, Zhang L, Zhou C . Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2007; 2(5):430-9. DOI: 10.1097/01.JTO.0000268677.87496.4c. View

Buonato J, Lazzara M . ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res. 2013; 74(1):309-19. PMC: 3964587. DOI: 10.1158/0008-5472.CAN-12-4721. View

Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G . HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009; 15(15):4829-37. PMC: 3372920. DOI: 10.1158/1078-0432.CCR-08-2921. View

Carolan H, Sun A, Bezjak A, Yi Q, Payne D, Kane G . Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?. Lung Cancer. 2005; 49(1):109-15. DOI: 10.1016/j.lungcan.2004.12.004. View

Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q . Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys. 2014; 89(2):330-7. DOI: 10.1016/j.ijrobp.2014.02.025. View

Eichler A, Kahle K, Wang D, Joshi V, Willers H, Engelman J . EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010; 12(11):1193-9. PMC: 3098020. DOI: 10.1093/neuonc/noq076. View

Zabel A, Debus J . Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy. Lung Cancer. 2004; 45 Suppl 2:S247-52. DOI: 10.1016/j.lungcan.2004.07.968. View

Italiano A, Burel Vandenbos F, Otto J, Mouroux J, Fontaine D, Marcy P . Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol. 2006; 17(6):981-5. DOI: 10.1093/annonc/mdl038. View

10.

Komaki R, Meyers C, Shin D, Garden A, Byrne K, Nickens J . Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 1995; 33(1):179-82. DOI: 10.1016/0360-3016(95)00026-U. View

11.

Ma X, Zhu H, Guo H, Han A, Wang H, Jing W . Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Oncotarget. 2016; 7(49):81906-81917. PMC: 5348441. DOI: 10.18632/oncotarget.11918. View

12.

Kalemkerian G, Akerley W, Bogner P, Borghaei H, Chow L, Downey R . Small cell lung cancer. J Natl Compr Canc Netw. 2013; 11(1):78-98. PMC: 3715060. DOI: 10.6004/jnccn.2013.0011. View

13.

Cortes J, Rodriguez J, Aramendia J, Salgado E, Gurpide A, Garcia-Foncillas J . Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 2002; 64(1):28-35. DOI: 10.1159/000066520. View

14.

Yavuz A, Topkan E, Onal C, Yavuz M . Prophylactic cranial irradiation in locally advanced non-small cell lung cancer: outcome of recursive partitioning analysis group 1 patients. J Exp Clin Cancer Res. 2008; 27:80. PMC: 2612647. DOI: 10.1186/1756-9966-27-80. View

15.

Shin D, Lee D, Kim C, Koh J, Lee J, Baek H . Epidermal growth factor receptor mutations and brain metastasis in patients with nonadenocarcinoma of the lung. J Cancer Res Ther. 2016; 12(1):318-22. DOI: 10.4103/0973-1482.154024. View

16.

Shaw A, Kim D, Mehra R, Tan D, Felip E, Chow L . Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370(13):1189-97. PMC: 4079055. DOI: 10.1056/NEJMoa1311107. View

17.

Sun D, Hu L, Cai Y, Li X, Ye L, Hou H . A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer. Asian Pac J Cancer Prev. 2014; 15(3):1233-9. DOI: 10.7314/apjcp.2014.15.3.1233. View

18.

Fidler I, Yano S, Zhang R, Fujimaki T, Bucana C . The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002; 3(1):53-7. DOI: 10.1016/s1470-2045(01)00622-2. View

19.

Dimitropoulos C, Hillas G, Nikolakopoulou S, Kostara I, Sagris K, Vlastos F . Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?. Cancer Manag Res. 2011; 3:287-94. PMC: 3173018. DOI: 10.2147/CMR.S22717. View

20.

Baik C, Chamberlain M, Chow L . Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015; 10(9):1268-1278. DOI: 10.1097/JTO.0000000000000615. View